 PALO ALTO, Calif., Aug. 5, 2021 PRNewswire -- BridgeBio Pharma, Inc. Nasdaq: BBIO BridgeBio or the Company, a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today reported its financial results for the second quarter ended June 30, 2021 and provided an update on the Companys operations. 